Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.
Company profile
Ticker
VIE
Exchange
Website
CEO
Zheng Bin Yao
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
VIE stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
25 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 21
POSASR
Automatic shelf registration (post-effective amendment)
15 Mar 21
8-K
Completion of Acquisition or Disposition of Assets
15 Mar 21
SC 14D9/A
Tender offer solicitation (amended)
15 Mar 21
25-NSE
Exchange delisting
15 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 21
10-K/A
2020 FY
Annual report (amended)
15 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
12 Mar 21
Latest ownership filings
SC 13D/A
Boundless Meadow Ltd
17 Mar 21
4
Yanling Cao
16 Mar 21
4
Tyrell Rivers
16 Mar 21
4
Change in insider ownership
16 Mar 21
4
Andreas Wicki
15 Mar 21
4
Edward Hu
15 Mar 21
4
Capital Opportunities Master Fund Boyu
15 Mar 21
4
Mitchell Chan
15 Mar 21
4
Jorn Drappa
15 Mar 21
4
James Paul Kastenmayer
15 Mar 21
Financial summary
Quarter (USD) | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 130.07 mm | 130.07 mm | 130.07 mm | 130.07 mm | 130.07 mm | |
Cash burn (monthly) | (no burn) | 5.90 mm | 11.24 mm | 12.82 mm | 905.92 k | |
Cash used (since last report) | n/a | 233.74 mm | 445.55 mm | 508.13 mm | 35.90 mm | |
Cash remaining | n/a | -103.68 mm | -315.48 mm | -378.07 mm | 94.17 mm | |
Runway (months of cash) | n/a | -17.6 | -28.1 | -29.5 | 103.9 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|